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ABSTRACT 
Background: There is increasing evidence that smoking is a risk factor for severe mental 
illness, including bipolar disorder. Conversely, patients with bipolar disorder might smoke 
more (often) as a result of the psychiatric disorder.  
Aims: We conducted a bidirectional Mendelian randomisation (MR) study to investigate the 
direction and evidence for a causal nature of the relationship between smoking and bipolar 
disorder. 
Method: We used publicly available summary statistics from genome-wide association studies 
on bipolar disorder, smoking initiation, smoking heaviness, smoking cessation and lifetime 
smoking (i.e., a compound measure of heaviness, duration and cessation). We applied 
analytical methods with different, orthogonal assumptions to triangulate results, including 
inverse-variance weighted (IVW), MR-Egger or Egger SIMEX, weighted median, weighted 
mode, and Steiger filtered analyses.  
Results: Across different methods of MR, consistent evidence was found for a positive effect 
of smoking on the odds of bipolar disorder (smoking initiation ORIVW=1.46, 95% CI=1.28-
1.66, P=1.44x10-8, lifetime smoking ORIVW=1.72, 95% CI=1.29-2.28, P=1.8x10
-4). The MR 
analyses of the liability to bipolar disorder on smoking provided no clear evidence of a strong 
causal effect (smoking heaviness betaIVW=0.028, 95% CI= 0.003-0.053, P=2.9x10
-2).  
Conclusions: These findings suggest that smoking initiation and lifetime smoking are likely to 
be a causal risk factor for developing bipolar disorder. We found some evidence that liability 
to bipolar disorder increased smoking heaviness. Given that smoking is a modifiable risk 
factor, these findings further support investment into smoking prevention and treatment in 
order to reduce mental health problems in future generations. 
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INTRODUCTION 
There is an increasing disparity in the prevalence of cigarette smoking between the general 
population and patients with severe mental illness, such as bipolar disorder.(1, 2) A meta-
analysis including worldwide studies showed that smoking rates are much higher in patients 
with bipolar than in the general population (OR 3.5, 95%CI 3.39-3.54).(2) This is important 
since smoking in bipolar disorder patients is associated with negative physical and mental 
health outcomes compared with non-smoking bipolar disorder patients.(3, 4) Smoking has 
been suggested as a risk factor for developing severe mental illness, including psychosis(5) 
and - to a lesser extent - bipolar disorder.(6-9) There is also an alternative explanation, namely 
that patients who suffer from bipolar disorder initiate smoking or increase existing smoking. 
In the latest genome-wide association study (GWAS) of smoking, smoking initiation and 
heaviness and bipolar disorder were not found to be genetically correlated.(10) Smoking and 
schizophrenia are genetically correlated.(10)  Nevertheless, smoking rates in bipolar disorder 
are also very high. A recent study showed furthermore that bipolar I disorder and 
schizophrenia and bipolar II disorder and major depressive disorder are highly correlated.(11) 
Moreover, previous findings support a causal relationship between smoking and other severe 
mental illnesses (e.g., schizophrenia and major depressive disorder).(12) It is, therefore, of 
interest to investigate the causal relationship between smoking and bipolar disorder. So far, 
very few observational studies have been used to investigate the relationship between 
smoking and bipolar disorder.(6) Observational results can be limited in their ability to 
determine causality, particularly due to residual confounding and reverse causation. 
Mendelian randomisation (MR) is a method that aims to overcome these limitations. 
Therefore, our aim was to investigate the direction and causal nature of the relationship 
between smoking and bipolar disorder using a bidirectional MR approach. Based on the 
current evidence(6, 7, 9) and a strong genetic correlation between bipolar disorder and 
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schizophrenia(11), we hypothesized that smoking is a causal risk factor for bipolar disorder. 
Based on conflicting clinical findings(8) and the fact that smoking initiation often precedes 
the onset of bipolar disorder symptoms, we hypothesized that the liability to bipolar disorder 
is not a causal risk factor for smoking. 
 
METHODS 
Mendelian randomisation 
In this study, genetic variants are used as instrumental variables and plausibility of the 
findings depends on assumptions. The three key assumptions are: The multiple genetic 
variants associate with the risk factor of interest, there are no unmeasured confounders of the 
associations between genetic variants and outcome, and the genetic variants affect the 
outcome only through their effect on the risk factor.(13) Pleiotropic effects refer to the effects 
of a genetic variant on multiple biological pathways, affecting the outcome either via the 
pathway under investigation, known as horizontal pleiotropy, or affect other traits through the 
risk factor, known as vertical pleiotropy.(14) Horizontal pleiotropy is problematic as it 
violates the third key assumption of MR.  
Data sources and genetic instruments 
In this MR study, multiple genetic variants that collectively explain some of the variance in 
the risk factors are used to investigate support for causal inferences with clinical outcomes. 
For smoking and bipolar disorder, genome-wide significant SNPs (P<5×10−8) from the most 
recently available GWASs were used as genetic instruments. No overlap existed in GWAS 
samples used for the exposure and outcome instruments. 
Smoking behavior 
  Smoking initiation 
For smoking initiation, we used summary data from the GSCAN GWAS as an exposure and 
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outcome variable. This GWAS identified 378 independent significant loci from a sample of 
1,232,091 individuals of European ancestry: these loci explained 2.3% of the variance in 
smoking initiation.(10) Data from the 23andMe sub-sample (n= 599,289) were excluded when 
smoking initiation was the outcome because genome-wide summary statistics were not 
available for the 23andMe sub-sample. Smoking initiation (yes/no) was defined as having 
smoked >100 cigarettes over the course of your life, smoked every day for at least a month or 
ever smoked regularly. The GSCAN GWAS provided effect sizes calculated from z-values 
weighted by the average prevalence across all studies. The effect sizes for smoking initiation 
as the outcome are, therefore, presented as betas and correspond to the increase of one 
standard deviation of prevalence of smoking initiation.(10)  
  Smoking heaviness and cessation 
In order to assess causal effects of smoking heaviness and smoking cessation on the risk for 
bipolar disorder, the analyses would have to be stratified into groups of smokers and non-
smokers. However, in the current two-sample MR study this was not possible due to a lack of 
data on smoking in the bipolar GWAS. Therefore, summary data about smoking heaviness 
and cessation from the GSCAN GWAS were used as an outcome variable only 
(Supplement).(10)  
 Lifetime smoking  
The recently developed lifetime smoking index is a measure that applies to all individuals 
(i.e., ever and never smokers), and among smokers it captures smoking severity, length of 
exposure and cessation. This instrument does not require stratification and is therefore the 
best proxy to investigate a ‘dose-response’-effect on the risk for bipolar disorder. Therefore, 
we used lifetime smoking summary data from the GWAS in the UK Biobank.(12) This 
GWAS of lifetime smoking identified 126 independent genome-wide significant SNPs in a 
sample of 462,690 individuals with European ancestry.(12) It has been validated in an 
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independent sample, where the 126 SNPs explained 0.36% of the variance in lifetime 
smoking, and against positive control disease outcomes (e.g., lung cancer).(12) 
Bipolar disorder 
For bipolar disorder as an exposure, we used summary statistics from the most recent GWAS 
comprising 20,352 cases from Europe, North-America and Australia and 31,358 controls of 
European descent.(15) The GWAS found 30 independent, genome-wide significant loci in the 
combined meta-analysis of the discovery GWAS and follow-up samples. This combined 
analyses also used 9,412 cases and 137,760 controls from follow-up samples. The polygenic 
risk score, including all measured genetic variants, accounted for about 8% of the variance in 
diagnosis. In this dataset, three clinically recognized subtypes of bipolar disorder were 
present: bipolar I disorder (n=14,879), bipolar II disorder (n=3,421) and schizoaffective 
disorder bipolar type (n=977).When bipolar disorder was the outcome, we used the one 
publicly available GWAS summary data made available by Psychiatric Genomics Consortium 
with a similar number of bipolar disorder cases and controls.(15)  
 
Statistical Analyses 
We used the MR Base Package(16) in R version 3.5.1(17) to harmonise SNP information and 
conduct bidirectional summary level MR analyses between smoking and bipolar disorder. The 
magnitude of the causal effect can be estimated by dividing the genetic variant-outcome 
association by the genetic variant-risk factor association.(18) Results were compared across 
the following methods: inverse-variance weighted (IVW), MR Egger(19) or Egger 
SIMEX(24), weighted median(20), weighted mode(21) and MR RAPS(22) (see 
supplementary materials for a comparison of each method and their assumptions). A 
consistent direction of effect across all of these methods strengthens causal evidence as each 
method makes different assumptions about pleiotropy.(23) Cochran’s Q (for IVW) and 
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Rucker’s Q (for MR Egger) statistics were therefore calculated to investigate heterogeneity 
between SNP causal effects and thus potential evidence of horizontal pleiotropy. Evidence of 
directional pleiotropy (whereby pleiotropic effects are biasing the estimates in the same 
direction) was also assessed using the MR Egger intercept. The difference between Cochran’s 
Q and Rucker’s Q statistics (Q’) was used to assess the extent to which MR Egger was a 
better fit to the data than the IVW method. The intercept from MR Egger provides a formal 
test for the presence of directional pleiotropy (whereby pleiotropic effects are biasing the 
estimates in the same direction). The validity of the MR Egger method was also evaluated 
using the weighted and unweighted regression dilution I2GX statistic.(24) For values of I
2
GX < 
0.9, MR Egger SIMEX corrections are presented using the highest of the two regression 
dilution statistics. For values of I2GX < 0.6, MR Egger and MR Egger SIMEX are unreliable 
and so neither are performed. Furthermore, mean F-statistics were calculated to assess the 
strength of the genetic instruments used.(25) As a rule of thumb, values of the mean F-statistic 
above 10 indicate that the results do not suffer from substantially weak instrument bias.(18) 
Lastly, we applied Steiger filtering to remove the genetic variants that explain more variance 
in the outcome than the exposure to avoid possible reverse causation.(26) For smoking 
initiation, lifetime smoking, and bipolar disorder, we reported the number of variants that 
were used in the bidirectional analyses after removing insertions or deletions and 
harmonisation of the data (Table 1). 
 
RESULTS 
Summary level Mendelian randomisation of smoking on bipolar disorder 
Across different methods of MR analyses, consistent evidence was found for a positive effect 
of smoking initiation on the odds of bipolar disorder (ORIVW=1.46, 95% CI=1.28-1.66, 
P=1.4x10-08) (see Table 1, Figure 1, Supplemental figures S1-S3). MR analyses using lifetime 
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smoking as the exposure variable showed significant effects in the same direction with a 
similar effect size (ORIVW=1.72, 95% CI= 1.89-2.28, P=1.8x10
-04) (see Table 1 and 
Supplemental figure S7-9). The I2GX suggested to use MR Egger SIMEX results (see 
Supplemental Table S1 and Table 1). Tests for heterogeneity suggest evidence for significant 
horizontal pleiotropy (see Supplemental Table S1), but MR Egger intercepts suggest that bias 
of the estimates by pleiotropy is not likely (see Supplemental Table S2). To explore whether 
the genetic variants for lifetime smoking and smoking initiation explained more variance in 
the exposure than in the outcome, Steiger filtering was applied. For smoking initiation, 20 
SNPS dropped out and 342/362 SNPS (94%) could be included after Steiger filtering. For 
lifetime smoking, 12 SNPS dropped out and 107/119 SNPs (90%) could be included in the 
analyses following Steiger filtering. The analyses were repeated across methods and similar 
effects were observed for smoking initiation and lifetime smoking on bipolar disorder 
(smoking initiation ORIVW=1.44, 95% CI=1.29-1.62, 1.0x10
-04; lifetime smoking 
ORIVW=1.47, 95% CI=1.17-1.83, P =7.9x10-04) (see Supplemental Table S5). Again, MR 
Egger was not conducted as I2GX values were below 0.9 (see Supplemental Table S1).  
 
---INSERT Figure 1. Scatter plot of IVW and MR Egger analyses of smoking initiation on 
bipolar disorder AROUND HERE--- 
---- INSERT TABLE 1. Bidirectional Mendelian randomisation analyses of the effects of 
smoking and bipolar disorder using summary level data AROUND HERE--- 
 
Summary level Mendelian randomisation of bipolar disorder on smoking 
The MR analyses of liability to bipolar disorder on risk of smoking initiation (betaIVW= -
0.008, 95% CI= -0.026-0.009, P=0.35), lifetime smoking (betaIVW= -0.001, 95% CI= -0.032-
0.030, P=0.95) and smoking cessation (ORVW= -0.003, 95% CI= 0.981-1.014, P=0.74) 
revealed no evidence of a causal effect (see Table 1 and Supplemental Figures S4-6 and S10-
12 and S16-18). MR analyses of liability to bipolar disorder on smoking heaviness (betaIVW= 
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0.028, 95% CI= 0.003-0.053, P=2.9x10-2) showed significant, small effects for MR IVW and 
MR RAPS but not MR weighted median or MR weighted mode (Table 1 and Supplemental 
Figure S13-S15). The I2GX suggested not to use MR Egger or MR Egger SIMEX results (see 
Supplemental Table S1). The tests for heterogeneity indicated no evidence for significant 
heterogeneity (Supplemental Table S2) and MR Egger intercepts suggested that bias of the 
estimates by horizontal pleiotropy is not likely (Supplemental Table S3). Steiger filtering 
indicated that all genetic variants for bipolar disorder explained more variance in bipolar 
disorder than smoking outcomes. The mean F-statistic also suggested that results were not 
subject to weak instrument bias (Supplemental Table S4). Although we did not find an effect 
using multiple genome-wide significant genetic variants, we noted that one SNP (rs3804640) 
stood out in particular showing a large, positive effect in the single SNP analysis of bipolar 
disorder to smoking initiation and lifetime smoking (Supplemental Figure S5 and S11). This 
SNP is an intron in the gene CD47, which encodes a membrane protein shown to play a role 
in synaptic plasticity in the hippocampus.(27-29)  
 
DISCUSSION 
The current study suggests that smoking is likely to be a causal risk factor for bipolar disorder 
by applying MR to two measures of smoking behaviour using GWAS summary statistics. In 
contrast, no evidence was found that liability to bipolar disorder has a causal effect on 
smoking initiation, smoking cessation or lifetime smoking. We found some evidence that 
suggested a small effect of liability for bipolar disorder on increased smoking heaviness. To 
the best of our knowledge, this is the first study providing robust evidence on the direction of 
the association between smoking and bipolar disorder. 
Mendelian randomisation of smoking on bipolar disorder 
When comparing the current findings to those of a previous study evaluating the relation 
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between smoking and other severe mental illnesses, the effect sizes we found are comparable 
to those testing lifetime smoking and smoking initiation as a risk factor for schizophrenia and 
major depressive disorder.(12) The evidence for smoking as a risk factor for bipolar disorder 
has been meager.(7-9) However, one conventional population-based birth cohort study found 
that maternal smoking was a risk factor for bipolar disorder in the offspring.(6) To rule out the 
effect of maternal smoking as an explanation of our results, future cohorts with measures of 
maternal and offspring smoking with enough bipolar cases are needed. In line with our 
findings, a study that used polygenic risk scores of smoking to predict bipolar disorder 
revealed a significant association but not vice versa.(30) Although this is suggestive of a 
causal effect, the current study adds to the body of evidence by overcoming residual 
confounding and providing an estimate of the causal effect size. The reported effect sizes of 
smoking in the current study are similar to other environmental risk factors (e.g. 
neurodevelopmental, substances and physical/psychological stress) for developing bipolar 
disorder as found in systematic reviews. (31, 32) Of note, the latter reviews included the 
following exposures as substance abuse: cocaine, cannabis, opioids, tranquilizers, smoking 
during pregnancy. We argue that tobacco use needs to be considered for inclusion in this list. 
 
Mendelian randomisation of bipolar disorder on smoking 
Although other studies have found an effect of bipolar disorder on smoking behavior(8), the 
current study did not replicate this finding for most smoking behaviours. The lack of an effect 
indicates that liability to bipolar disorder is not a risk factor for smoking initiation, cessation 
or lifetime smoking. From a methodological point of view, one might explain the lack of a 
clear effect of the liability to bipolar disorder on smoking initiation, cessation and lifetime 
smoking by using weaker instruments for bipolar disorder as compared with smoking. This 
would result in reduced statistical power to detect a causal effect. However, we argue that this 
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explanation is unlikely since the effect sizes consistently show values around the null, 
confidence intervals were small and the mean F-statistic, which is a proxy for the strength of 
the instrumental variable, showed an acceptable value. The results of the liability to bipolar 
disorder on smoking heaviness suggested from two MR methods a significant, small effect 
and from two other methods no significant effect. This could indicate that liability to bipolar 
disorder increases smoking heaviness or there might be a bias from pleiotropy. Of note, MR 
typically investigates long-term effects of liability to bipolar disorder on life-time smoking 
behaviour and firm conclusions on acute transient effects (e.g., more severe bipolar symptoms 
increasing heaviness of smoking) could, therefore, not be drawn.  
 
Strengths and limitations 
A strength of this study is the substantial power, since we used summary data from recent, 
large GWAS consortia to conduct a summary level MR.(33) Also, using genetic variants to 
determine the effects reduces the chance of reverse causation and residual confounding.(34) 
Furthermore, a consistent effect across different methods increases the confidence in most of 
our findings.(23) Some limitations should be noted. First, the GWAS were conducted in 
individuals from European ancestry which could limit generalizability to other populations. 
Second, although the smoking instruments capture smoking initiation, duration, heaviness and 
cessation, the instruments cannot be used to determine effects at specific life stages. The 
results should be interpreted as cumulative effects of smoking over the life course (potentially 
from conception and potentially from second hand smoke from family members). In other 
words, it is not certain that our findings regarding smoking are confined to a specific period. 
Third, we assumed that the exclusion restriction criteria hold since the MR-Egger intercept 
test for directional horizontal pleiotropy was not significant. Still, pleiotropy could be in place 
as regression dilution values pointed that Egger results might not be trustworthy. The 
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underlying biological process of mental illnesses are relatively poorly understood which 
complicates the possibility to disentangle the plausibility of potential pathways. For example, 
genetic variants that were significantly associated with smoking initiation coded for several 
biologically plausible pathways such as acetylcholine nicotinic receptors and glutamate 
pathways that affect reward processing and addiction.(10) However, general biological 
pathways such as sodium, potassium and calcium voltage-gated channels were also implied, 
potentially overlapping with horizontal pleiotropic pathways. Nevertheless, results after 
Steiger filtering (e.g., testing whether the SNP explains more variance in the exposure or 
outcome and only selecting those explaining more in the outcome) showed similar effects of 
smoking on bipolar disorder. Although unlikely, pleiotropic effects can still be in place. 
Fourth, genetic vulnerability for smoking could also be related to environmental factors that 
are associated with the outcome which could lead to spurious causal effects. Nevertheless, the 
consistent findings across all sensitivity analyses with different assumptions point towards 
robust findings. Unlike the prospective and longitudinal evidence concerning smoking and 
psychosis, epidemiological research regarding smoking as a risk factor for bipolar disorder is 
scarce. Future studies are needed to triangulate the evidence further. Fifth, sensitivity analyses 
into bipolar subtypes could not be performed due to a low number of associated genetic 
variants. Future GWAS with larger sample sizes are required to potentially overcome this 
issue. Lastly, the bipolar disorder GWAS has a relatively low number of associated loci and a 
smaller sample compared to the smoking GWAS. Future GWAS with larger samples of 
bipolar patients could yield a higher number of associated SNPs. An increase in the 
percentage of explained variance could alter MR results. 
Possible mechanisms 
There are several, non-mutually exclusive, plausible explanations for causal pathways from 
smoking to bipolar disorder.(7-9) First, nicotine binds to subtypes of the nicotinic 
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acetylcholinergic receptor which is implicated in the regulation of central nervous system 
pathways relevant to mood disorders.(35) Although the quality of the evidence is low, several 
case studies have related the use of a partial nicotine receptor agonist (varenicline) to induced 
mania or new onset of bipolar disorder.(36-41) Second, nicotine exposure leads to 
desensitization of the nicotine acetylcholinergic receptor by phospohorylation of subunits.(42) 
These dysmorphic receptors then have reduced binding capacity for endogeneous 
acetylcholine: craving on drug withdrawal is clear evidence of changed function in reward 
pathways. The reduced functioning of these receptors could have an effect on 
neurotransmitter levels and subsequently lead to a higher vulnerability to develop bipolar 
disorder, although evidence about this topic is lacking. Third, burning tobacco releases toxic 
compounds which induce inflammation and oxidative stress which may be associated with 
bipolar disorder.(35)  
 
Clinical implications 
Many hypotheses exist to explain the high prevalence of smoking in severe mental illness.(43) 
The lack of a consistent, bidirectional effect and the causal evidence that smoking initiation 
liability increases the risk for bipolar disorder point toward the two-hit or diathesis-stress 
model.(44) This implies a neurobiological vulnerability for severe mental illness(45) 
interacting with an environmental stressor, such as smoking, leading to an increased 
vulnerability for severe mental illness.(44) Several studies have shown that smoking in 
adolescents and adults with bipolar disorder is associated with earlier age at onset of mood 
disorder, greater severity of symptoms(46-51), poorer functioning, comorbid substance 
abuse(52), suicide attempts(53) and other adverse outcomes such as readmission(54). Our 
results underline the importance of strategies to prevent adolescents from starting smoking 
and treat smoking in bipolar patients. The frequently mentioned reason for smoking by 
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bipolar patients is stress-coping behavior(55) and a tailored prevention strategy might be 
helpful in learning healthy coping strategies. Regardless of the mechanism which may 
eventually be confirmed, our findings underline the importance of prevention and treatment 
programs to reduce smoking and its consequences. Investing in a smoke free future could 
reduce mental health problems in future generations. 
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